

Research article

Open Access

S-Nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner

Tarja Kokkola¹, Juha R Savinainen^{1,2}, Kati S Mönkkönen¹,
Montse Durán Retamal¹ and Jarmo T Laitinen*¹

Address: ¹Department of Physiology, University of Kuopio, POB 1627, FIN-70211, Kuopio, Finland and ²Department of Pharmaceutical Chemistry, University of Kuopio, POB 1627, FIN-70211 Kuopio, Finland

Email: Tarja Kokkola - tarja.kokkola@uku.fi; Juha R Savinainen - juha.savinainen@uku.fi; Kati S Mönkkönen - kati.monkkonen@uku.fi; Montse Durán Retamal - monsdrr@hotmail.com; Jarmo T Laitinen* - jarmo.laitinen@uku.fi

* Corresponding author

Published: 25 April 2005

Received: 05 November 2004

BMC Cell Biology 2005, **6**:21 doi:10.1186/1471-2121-6-21

Accepted: 25 April 2005

This article is available from: <http://www.biomedcentral.com/1471-2121/6/21>

© 2005 Kokkola et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Recent studies indicate that the G protein-coupled receptor (GPCR) signaling machinery can serve as a direct target of reactive oxygen species, including nitric oxide (NO) and S-nitrosothiols (RSNOs). To gain a broader view into the way that receptor-dependent G protein activation – an early step in signal transduction – might be affected by RSNOs, we have studied several receptors coupling to the G_i family of G proteins in their native cellular environment using the powerful functional approach of [³⁵S]GTPγS autoradiography with brain cryostat sections in combination with classical G protein activation assays.

Results: We demonstrate that RSNOs, like S-nitrosoglutathione (GSNO) and S-nitrosocysteine (CysNO), can modulate GPCR signaling via reversible, thiol-sensitive mechanisms probably involving S-nitrosylation. RSNOs are capable of very targeted regulation, as they potentiate the signaling of some receptors (exemplified by the M2/M4 muscarinic cholinergic receptors), inhibit others (P2Y₁₂ purinergic, LPA, lysophosphatidic acid, and cannabinoid CB₁ receptors), but may only marginally affect signaling of others, such as adenosine A₁, μ-opioid, and opiate related receptors. Amplification of M2/M4 muscarinic responses is explained by an accelerated rate of guanine nucleotide exchange, as well as an increased number of high-affinity [³⁵S]GTPγS binding sites available for the agonist-activated receptor. GSNO amplified human M4 receptor signaling also under heterologous expression in CHO cells, but the effect diminished with increasing constitutive receptor activity. RSNOs markedly inhibited P2Y₁₂ receptor signaling in native tissues (rat brain and human platelets), but failed to affect human P2Y₁₂ receptor signaling under heterologous expression in CHO cells, indicating that the native cellular signaling partners, rather than the P2Y₁₂ receptor protein, act as a molecular target for this action.

Conclusion: These in vitro studies show for the first time in a broader general context that RSNOs are capable of modulating GPCR signaling in a reversible and highly receptor-specific manner. Given that the enzymatic machinery responsible for endogenous NO production is located in close proximity with the GPCR signaling complex, especially with that for several receptors whose signaling is shown here to be modulated by exogenous RSNOs, our data suggest that GPCR signaling in vivo is likely to be subject to substantial, and highly receptor-specific modulation by NO-derived RSNOs.

Background

G protein-coupled receptors (GPCRs) represent the largest group of integral membrane proteins involved in signal transduction and are the most important targets of clinically marketed drugs [1-3]. The known GPCRs mediate messages from ligands as diverse as neurotransmitters, lipid mediators, hormones, and sensory stimuli [4]. The classical scheme of GPCR signaling implies that agonist-induced conformational changes in receptor molecule will result in activation of cognate G proteins and subsequently in the regulation of downstream effectors, second messengers, and the activation of protein kinases, for example [4]. However, recent work has indicated that GPCR signaling is subject to complex, cell-type specific regulation, involving a plethora of kinases, as well as newly-identified signaling partners, such as regulators of G protein signaling (RGS) [5], and activators of G protein signaling (AGS) [6].

Nitric oxide (NO) is a unique gaseous messenger generated *in vivo* by three isoforms of NO synthases (NOS). The established mode of NO signaling is through the activation of the hemoprotein, soluble guanylyl cyclase, resulting in increased production of the second messenger cGMP. However, accumulating evidence points towards cGMP-independent mechanisms by which NO can react with proteins, forming covalent post-translational modifications [7]. S-nitrosothiols (RSNOs) are biological metabolites of NO, that may prolong and spatially extend the *in vivo* actions of locally produced NO [8]. NO and RSNOs can reversibly react with free SH-groups of target cysteine (Cys) residues, including those in proteins, leading to S-nitrosylation and/or S-thiolation (disulfide linkage of low-molecular weight thiols to proteins) [8-17]. A broad functional spectrum of potential S-nitrosylation target proteins is currently recognized. A growing list of targets include ion channels, transporters, transcription factors, signaling proteins, metabolic enzymes, as well as respiratory proteins [7,14,18-20]. Although individual components of the GPCR signaling machinery are implicated as potential targets of reactive oxygen species (ROS), including NO [21-35], a broader view on how NO, and RSNOs in particular, might modulate GPCR signaling, has not been established.

To begin to address these issues, we have studied how exogenous RSNOs affect receptor-mediated G protein activity – a very proximal step of GPCR signal transduction – by studying the signaling of several receptors that couple to the G_i family of heterotrimeric G proteins. This family consists of both pertussis toxin sensitive (G_{α_{i1-3}}, G_{α_o}, transducin, gustducin) and insensitive (G_{α_z}) members. We applied the powerful functional approach of [³⁵S]GTPγS autoradiography in brain cryostat sections, as this technique allows selective detection of receptor-

dependent G protein activity simultaneously in multiple brain regions with minimal disturbance of the GPCR microenvironment [36]. We anticipated that accessibility of target thiols would be minimally disturbed in cryostat sections. Moreover, it is increasingly recognized that specialized plasma membrane microdomains (variously described as detergent-resistant fractions, low-density fractions, lipid rafts, or caveolae) act as unique signaling platforms with specific enrichment of GPCRs, their cognate G proteins, as well as effectors [37-40]. Such an enrichment is thought to be well-preserved in cryostat sections, but might be compromised to a variable extent [38], or even lost in bulk membrane preparations obtained using traditional protocols. To complement the autoradiography approach, we used membrane and lysate [³⁵S]GTPγS binding assays to more systematically study the effects of RSNOs on a panel of G_i-coupled receptors in native tissues. Signaling of selected receptors was further studied after their heterologous expression in Chinese hamster ovary (CHO) cells. Our studies reveal highly receptor-specific modulation of GPCR signaling by RSNOs, as signaling of some receptors can be amplified, or inhibited, whereas for others, the activity is only marginally affected by comparable treatments. The GPCR itself and/or its native signaling partners seem to act as potential targets of RSNO action, and therefore their modulation may be diminished, or even totally masked under heterologous expression.

Results

Exogenous RSNOs modulate GPCR signaling via mechanisms likely involving S-nitrosylation

We used the functional approach of [³⁵S]GTPγS autoradiography, as this technique allows selective detection of receptor-stimulated G_i protein activity simultaneously in multiple brain structures with minimal disturbance of the GPCR microenvironment [36]. We focused the initial experiments on three G_i-linked receptors, namely M2/M4 AChRs, the P2Y₁₂ purinoceptor, and the LPA₁ receptor, as G protein activity upon stimulation of these receptors has been previously characterized using the autoradiography approach and each receptor shows a unique anatomical distribution pattern in the developing rat brain [36,41-43]. As depicted in Figure 1, pretreatment of brain sections with freshly prepared GSNO (0.5 mM) had distinct effects on basal and receptor-stimulated [³⁵S]GTPγS binding responses. In GSNO-treated sections, basal G protein activity was increased throughout the gray matter areas and this effect was fully reversed in the presence of excess thiol, either in the form of dithiotreitol (DTT) or reduced glutathione (GSH). The autoradiography images were quantified for selected brain regions and these results are shown in Supplementary Figures 1 and 2 [see additional file 1]. Consistent with the anatomical distribution of atropine-sensitive and M2/M4 AChR-dependent G





Figure 1
S-nitrosoglutathione (GSNO) reversibly modulates basal and receptor-dependent G protein activity in rat brain cryostat sections. [³⁵S]GTPγS autoradiography of sagittal brain sections was conducted using a 3-step protocol with DPCPX (10⁻⁶ M) present throughout steps 2 and 3, as detailed in the *Methods* section. Where indicated, GSNO (0.5 mM) was present for 60 min during the GDP loading (step 2). When used, DTT (1 mM) or GSH (1 mM) were present during the [³⁵S]GTPγS labeling (step 3). The muscarinic agonist, carbachol (CCh, 10⁻⁴ M), the P2Y receptor agonist 2-methylthio-ADP (2MeSADP, 10⁻⁵ M) or lysophosphatidic acid (LPA, 5 × 10⁻⁵ M in 0.1% fatty acid free BSA) were present in step 3. In the control panel (left), the anatomical loci where receptor agonists typically activate G proteins are indicated. Note GSNO-dependent overall increase in basal G protein activity, as well as robust amplification of CCh-stimulated G protein activity in several gray matter regions visible at this sagittal plane, most notably the brain stem (bs) nuclei, the striatum (Str), and the superficial gray layer of the superior colliculus (SuG). Note also clear attenuation of 2MeSADP-stimulated responses in all brain regions, and blunting of LPA-stimulated responses, especially in the white matter areas, including the corpus callosum (cc), the fimbria of the hippocampus (fi) and the cerebellar white matter (Cbw). Scale bar = 2 mm. For quantitative data on selected brain regions, see Supplementary Figs. 1 and 2 in additional file 1.

protein activity [36,44,45], the cholinergic agonist carbachol (CCh) stimulated [³⁵S]GTPγS binding to multiple gray matter regions, including the striatum (Str), the thalamic structures, with the most intense responses in the superficial gray layer of the superior colliculus (SuG), as well as various brainstem (bs) nuclei. In all visible regions, CCh-stimulated G protein activity was robustly amplified by GSNO. This was particularly evident in the above-mentioned M2/M4 receptor-enriched anatomical loci. It is noteworthy that the GSNO effects were fully reversed in all regions in the presence of DTT or GSH (Figure 1, Supplementary Figure 1 [see additional file 1]). As further illustrated in Figure 1, the P2Y receptor agonist 2-methylthio-ADP (2MeSADP) activated G proteins both in gray and white matter regions, producing a heterogeneous activity pattern with characteristic "hot spot" appearance,

as described earlier [41,42]. Previous studies have established that the 2MeSADP-stimulated G protein activity in rat brain sections is mediated by a P2Y receptor subtype that pharmacologically corresponds to P2Y₁₂ [41,42]. In contrast to the robust amplification of M2/M4 receptor-dependent G protein activity, GSNO clearly inhibited P2Y₁₂ receptor signaling (Figure 1, Supplementary Figures 1 and 2 [see additional file 1]). This inhibition was evident throughout the effective agonist concentration range (10⁻⁷ - 10⁻⁴ M 2MeSADP), and responses to the endogenous agonist ADP (5 × 10⁻⁵ - 10⁻³ M) were similarly blunted (Supplementary Figure 2 [see additional file 1]). The GSNO-effect was fully reversible upon addition of DTT or GSH (Figure 1, Supplementary Figure 1 [see additional file 1]). In the developing rat brain, LPA-stimulated G_i protein activity is largely restricted to the myelinating

**Figure 2**

GSNO modulates GPCR signaling in a dose-dependent manner. [³⁵S]GTPγS autoradiography was conducted using a 3-step protocol with DPCPX (10⁻⁶ M) present throughout steps 2 and 3, as detailed in the *Methods* section. GSNO was present at the indicated concentrations for 60 min during the GDP loading (step 2). Carbachol (CCh, 10⁻⁴ M), 2MeSADP (10⁻⁶ M) or LPA (5 × 10⁻⁵ M in 0.1% fatty acid free BSA) were present in step 3. Note dose-dependent amplification of CCh-stimulated G protein activity, most evident at this coronal plane in the cerebral cortex (Cx), the striatum (Str), and the thalamus (Thal). Note also dose-related attenuation of 2MeSADP- and LPA-stimulated responses, especially in the white matter regions, including the corpus callosum (cc), the fimbria of the hippocampus (fi), and the striatal white matter (Sw). Scale bar = 2 mm. For quantitative data on selected brain regions, see Supplementary Figs. 1 and 2 in additional file 1.

white matter tracts [36,41,43] (Figure 1), closely reflecting the anatomical distribution of LPA₁ receptor subtype [Ref. 36, and references therein]. Similar to the P2Y₁₂ responses, LPA₁ receptor responses were suppressed in GSNO-treated sections throughout the white matter tracts. Also this effect was fully reversed in the presence of thiols (Figure 1, Supplementary Figure 1 [see additional file 1]).

GSNO is present in significant amounts (~15 pmol/mg protein) in the brain tissue and it is thought to act as a physiological carrier of NO for S-nitrosylation reactions [46,47]. As shown in Figure 2 and Supplementary Figure 1 [see additional file 1], GSNO modulated GPCR responses in a dose-dependent manner, being effective at the submillimolar concentration range. However, the threshold and maximal concentrations needed for the modulation of distinct receptors slightly varied. Potentiation of M2/M4 receptor signaling was evident already with 0.05 mM GSNO, but statistically significant responses were obtained using 0.2 – 1 mM GSNO (Supplementary Figure 1 [see additional file 1]). P2Y₁₂ receptor responses were inhibited with 0.2 mM GSNO and higher concentrations (Figure 2, Supplementary Figure 1 [see additional file 1]). LPA₁ receptor signaling was only marginally affected with 0.05 mM GSNO, but was severely blunted with 0.2 mM GSNO and higher concentrations (Figure 2, Supplementary Figure 1 [see additional file 1]). Collectively, these experiments demonstrate that GSNO, a physiologically relevant RSNO, can modulate GPCR signaling in discrete brain regions in a receptor-specific and fully reversible manner.


Various RSNOs, including S-nitrosocysteine (CysNO) (Figure 3, Supplementary Table 1 [see additional file 1]), S-nitrosocysteamine, S-nitroso-L-cysteinylglycine (CysNO-Gly), L-γ-glutamyl-S-nitrosocysteine (Glu-CysNO), and S-nitroso-N-acetyl-D,L-penicillamine (SNAP) – a compound with a sterically hindered SNO group – mimicked the effects of GSNO on the three studied receptors (Figure 3, Supplementary Figure 2 [see additional file 1], and data not shown). When equimolar concentrations (0.5 mM) of GSNO and SNAP were compared, SNAP equally well suppressed P2Y₁₂ receptor responses, whereas GSNO more efficiently modulated M2/M4 and LPA₁ receptor responses (Supplementary Figure 3 [see additional file 1]). The modulatory effect of CysNO on the three receptors was reversed by addition of DTT or cysteine (Supplementary Figure 4 [see additional file 1]). However, when "aged" CysNO was used (the stock solution was left to stand for 2 days in ambient light, oxygen and temperature), receptor-stimulated G protein activity was almost completely abolished (Supplementary Figure 5 [see additional file 1]).

Previous studies have suggested that RSNOs can act as NO⁺, NO[•], and NO⁻ donors under physiological conditions [9]. The RSNO effects on GPCR responses were not mimicked by the NO donor sodium nitroprusside (SNP), when tested at similar (0.5 mM) concentrations (Figure 3, Supplementary Table 1 [see additional file 1]). Furthermore, the NO⁺-releasing NO donor, nitrosodium tetrafluoroborate (NOBF₄, 0.5 mM) (data not shown), hydrogen peroxide (1 mM H₂O₂ + 0.2 mM FeSO₄) (data not shown), or the cyclic GMP analog 8-bromo-cyclic GMP (0.25 mM) (Figure 3, Supplementary Table 1 [see additional file 1]) were largely ineffective. For selected brain regions, quantitative autoradiography data on CysNO, SNP and 8-bromo-cyclic GMP are presented in the Supplementary Table 1 [see additional file 1].

The above results demonstrate that the effects of NO-related species was shared by -and restricted to - different classes of RSNO compounds, suggesting that S-nitrosylation rather than other types of NO reactions, or cGMP-dependent mechanisms, were involved. According to the S-nitrosylation scheme, treatment with exogenous RSNOs should result in transnitrosylation of potential protein thiols (R-SNO + Protein-SH ↔ R-SH + Protein-SNO). To demonstrate the presence of SNO moieties in GSNO-treated brain section, we used the indirect approach where heterolytic cleavage of S-NO bond with HgCl₂ generates nitrite which can be measured by a colorimetric method. To this end, brain sections were treated with GSNO (0.5 mM), and after thorough washes, the sections were incubated further in the absence or presence of HgCl₂ (10⁻⁴ M). These experiments (shown in Supplementary Figure 6 [see additional file 1]) revealed that HgCl₂-catalyzed nitrite formation was significantly higher in GSNO treated sections than that in control conditions (2.46 ± 0.13 vs. 0.61 ± 0.14 nmol NO₂⁻ per four coronal brain sections, mean ± SE, n = 3, P < 0.001). Collectively these experiments suggest that the RSNO-evoked and receptor-specific modulation of GPCR signaling in brain sections most likely involves S-nitrosylation mechanisms.

RSNOs modulate GPCR signaling in native tissues in a highly receptor-specific manner

Although [³⁵S]GTPγS autoradiography offers the advantage of monitoring G protein activity simultaneously in multiple brain regions with minimal disturbance of the GPCR microenvironment, generating quantitative data from the autoradiography images is relatively tedious. As a complementary approach, we tested the effect of RSNOs on agonist potency and efficacy for several additional G_i-coupled receptors using classical membrane and lysate [³⁵S]GTPγS binding assays. The results of these experiments are summarized in Table 1. There was one major difference from the situation with brain sections; in the rat forebrain membrane preparations GSNO did not

**Figure 3**

S-nitrosocysteine (CysNO) mimics the effects of GSNO in modulating GPCR signaling, whereas sodium nitroprusside (SNP) and 8-bromo cyclic GMP (8Br-cGMP) do not. [³⁵S]GTP γ S autoradiography was conducted using a 3-step protocol with DPCPX (10^{-6} M) present throughout steps 2 and 3, as detailed in the *Methods* section. Where indicated, CysNO (1 mM), SNP (0.5 mM), or 8Br-cGMP (0.25 mM) were present for 60 min during the GDP loading (step 2). Carbachol (10^{-4} M), 2MeSADP (10^{-6} M), or LPA (5×10^{-5} M in 0.1% fatty acid free BSA) were present in step 3. Note amplification of CCh-stimulated G protein activity by CysNO, most evident at this coronal plane in the cerebral cortex (Cx), the thalamus (Thal), including the superficial gray layer of the superior colliculus (SuG). Note also CysNO-dependent attenuation of 2MeSADP- and LPA-stimulated responses, most evident in the corpus callosum (cc) and the fimbria of the hippocampus (fi). Scale bar = 2 mm. For quantitative data on selected brain regions, see Supplementary Table 1 in additional file 1.

Table 1: Effects of GSNO treatment on agonist dose-response parameters in [³⁵S]GTPγS binding assays of various G_i-coupled receptors in their native cellular environment. Membranes or lysates were preincubated in control conditions or in the presence of 0.5 mM GSNO for 30 min. Values are mean ± SE from three to four independent experiments performed in duplicate. E_{max} is expressed in percentage over basal with nonspecific binding subtracted.

Receptor (agonist)	Control		GSNO	
	log(EC ₅₀)	E _{max} (%)	log(EC ₅₀)	E _{max} (%)
Rat forebrain membranes				
M2/M4 mAChRs (CCh)	-4.94 ± 0.05	176 ± 2	-5.55 ± 0.11**	207 ± 4**
LPA ₁ (LPA)	-6.84 ± 0.26	140 ± 7	-6.53 ± 0.40	116 ± 3*
Cannabinoid CB ₁ (CP55940)	-7.84 ± 0.07	223 ± 3	-7.69 ± 0.08	183 ± 2***
Adenosine A ₁ (2ClAdo)	-6.90 ± 0.04	256 ± 3	-6.87 ± 0.12	234 ± 7*
μ-opiate (DAMGO)	-6.85 ± 0.09	167 ± 3	-7.31 ± 0.19	164 ± 5
ORL1 (Nociceptin)	-8.66 ± 0.12	173 ± 3	-8.78 ± 0.10	161 ± 2*
CHO cell lysates				
LPA (LPA)	-7.37 ± 0.11	202 ± 4	-7.05 ± 0.12	176 ± 4**
Human platelet membranes				
P2Y ₁₂ (MeSADP)	-8.19 ± 0.03	279 ± 2	-8.30 ± 0.08	195 ± 3***
α _{2A} -adrenoceptor (NA)	-5.33 ± 0.08	161 ± 2	-5.49 ± 0.09	182 ± 3**

* Statistically different from control (P < 0.05)

** Statistically different from control (P < 0.01)

*** Statistically different from control (P < 0.001)

significantly affect basal G protein activity (102 ± 2 % control, mean ± SE, n = 26, see also Figures 6 and 7). However, GSNO modulation of receptor-mediated responses was found to be highly receptor-specific. In line with the autoradiography data, M2/M4 receptor signaling was markedly amplified (both the potency and the efficacy of agonist increased) whereas LPA-evoked signaling efficacy (but not agonist potency) was significantly decreased in the rat forebrain membrane preparations. Moreover, the efficacy of cannabinoid CB₁ receptor signaling was significantly inhibited with no concomitant change in agonist potency (Table 1). [³⁵S]GTPγS autoradiography studies further indicated that CB₁ receptor signaling was similarly inhibited in various CB₁ receptor-enriched brain regions, including the cerebral cortex, the hippocampus and the globus pallidus (Supplementary Figure 7 [see additional file 1]). On the other hand, signaling via other widely distributed receptors, such as adenosine A₁, μ-opioid (MOR) and opiate-related receptor (ORL1), was only marginally (A₁ and ORL1), or not detectably (MOR), altered in bulk membrane preparations (Table 1) or in brain cryostat sections (Figure 4). For the three receptors, quantitative autoradiography data on selected brain regions are presented in Supplementary Table 2 [see additional file 1].

CHO cells express endogenous G_i-coupled LPA receptors [48-50], and similarly to the situation in brain membranes and cryostat sections, GSNO significantly inhibited LPA signaling in CHO cell lysates without affecting the agonist potency (Table 1). Platelets offer another read-

ily accessible model to study P2Y₁₂-G_i (specifically Gα₁₂) signaling in native cellular environments [42,51,52]. In human platelet membranes, GSNO inhibited basal G protein activity by 22 ± 4 % (mean ± SE, n = 3). This effect was statistically significant. Similar to the situation with brain P2Y₁₂ receptor signaling, GSNO inhibited P2Y₁₂ receptor-dependent G protein activity in human platelet membranes, but had no effect on the agonist potency (Table 1). To examine whether the receptor protein serves as a direct target of this action, human P2Y₁₂ receptor was stably transfected into CHO cells. Several cell lines responding to 2MeSADP in [³⁵S]GTPγS binding assays were established (our unpublished observations). However, neither GSNO nor CysNO affected the 2MeSADP dose-response curves of any of the hP2Y₁₂-expressing cell lines (Figure 5 and data not shown). These data rule out the P2Y₁₂ receptor protein as a direct target of the RSNO action.

The inhibitory effect of GSNO on basal and P2Y₁₂ receptor-dependent G protein activity was not due to a nonspecific action on platelet membranes, since the signaling of another G_i-linked platelet receptor, the α_{2A}-adrenoceptor, was significantly amplified in GSNO-treated membranes (Table 1). This effect was not restricted to platelets, nor was it unique to the α_{2A}-subtype, as signaling of the three human α₂-adrenoceptor subtypes (α_{2A}, α_{2B}, and α_{2C}) was potentiated by GSNO in CHO cell lines stably expressing these receptors (our unpublished observations).




Figure 4
GSNO only marginally affect opiate related receptor (ORL1), μ opioid receptor (MOR) and adenosine A₁ (Ado A₁) receptors signaling in brain sections.
 [³⁵S]GTP γ S autoradiography was conducted using a 3-step protocol with adenosine deaminase (ADA, 1 U/ml) present throughout steps 2 and 3, as detailed in the *Methods* section. Where indicated, GSNO (1 mM) was present for 60 min during the GDP loading (step 2). Protease inhibitor cocktail was included in step 2 for brain sections used for testing ORL1 and MOR responses. Receptor agonists nociceptin (ORL1), DAMGO (MOR), and 2-chloroadenosine (2CIAdo) (adenosine A₁ receptor) were present at submaximal concentrations during step 3. Note wide distribution of nociceptin-responsive brain regions, including the cerebral cortex (Cx). Note also robust response to DAMGO in the MOR-enriched striatal patches (Sp), as well as the relatively GSNO-resistant, and widely distributed adenosine A₁ receptor-dependent signal throughout the sagittal plane. Scale bar = 2 mm. For quantitative data on selected brain regions, see Supplementary Table 2 in additional file 1.




Figure 5
The P2Y₁₂ receptor is not a direct target of RSNO action. Human P2Y₁₂ receptor was stably expressed in CHO cells and agonist-stimulated G protein activity was determined in control conditions and in membranes pre-treated for 30 min with 0.5 mM GSNO or CysNO, as detailed in the *Methods* section. There were no statistical differences in the agonist potency [$\log(EC_{50})$: control -9.20 ± 0.09 ; GSNO -9.14 ± 0.07 ; CysNO -9.27 ± 0.14] or efficacy [E_{max} (% basal): control $182 \pm 3\%$; GSNO 180 ± 2 ; CysNO $179 \pm 5\%$]. Values are mean \pm SE from three independent experiments performed in duplicate.

RSNOs amplify muscarinic responses by increasing the rate of GDP/GTP exchange and the number of high-affinity GTP binding sites

The amplification of M2/M4 responses by RSNOs was clearly evident in native brain tissue. Further experiments were designed to address the mechanism of this action. Results of these studies are presented in Figures 6 and 7. A time-response study on basal and CCh-stimulated [³⁵S]GTP γ S binding responses in forebrain membranes revealed that GSNO accelerated the rate of [³⁵S]GTP γ S binding in agonist-stimulated conditions (Figure 6). In contrast, GSNO had no effect on basal guanine nucleotide exchange. Given that GDP release is generally thought to be the rate-limiting step in receptor-driven G protein activation, these data indicate that the amplifying effect of GSNO on M2/M4 receptor-stimulated G protein activity is due to an accelerated rate of GDP/GTP exchange at the receptor-activated G protein α subunits. In line with this, GSNO significantly increased the number of high-affinity [³⁵S]GTP γ S binding sites available for M2/M4 receptor activation under agonist-stimulated conditions (Figure 7)




Figure 6
GSNO accelerates the rate of M2/M4 AChR-stimulated [³⁵S]GTP γ S binding to rat forebrain membranes but has no effect on basal guanine nucleotide exchange rate. Membranes were preincubated for 30 min in control conditions or in the presence of 0.5 mM GSNO, and time-response for basal and CCh-stimulated (10^{-4} M) [³⁵S]GTP γ S binding was determined, as detailed in the *Methods* section. Values represent specific binding (mean \pm SD of duplicate determinations) from one representative experiment that was replicated three times with similar outcome.

(Mean \pm SE: CCh-control 1.49 ± 0.02 vs. CCh-GSNO 1.75 ± 0.02 pmol/mg protein, $P < 0.001$, unpaired T-test). In contrast, there were no statistical differences in the potency of GTP γ S to displace [³⁵S]GTP γ S in any of the tested conditions (Figure 7) [$\log(EC_{50}) \pm$ SE: basal-control -8.10 ± 0.07 ; basal-GSNO -8.11 ± 0.12 ; CCh-control -8.06 ± 0.06 ; CCh-GSNO -8.10 ± 0.04]. These experiments indicate that RSNOs amplify muscarinic receptor-stimulated G protein activity in native brain tissue by accelerating the rate by which agonist-occupied receptors can activate their cognate G proteins.

RSNO amplification of M4 receptor responses are preserved under heterologous expression but the amplification is lost with constitutive receptor activity

To investigate the signaling of the human M4 receptor (hM4) under heterologous expression system, the receptor was stably transfected into CHO cells. The effects of GSNO on agonist-stimulated G protein activity were compared in rat forebrain membranes and three cell lines expressing the wild-type (WT) hM4 receptor with increasing capability to activate G proteins. The results of these experiments are shown in Figure 8, and the potency and efficacy values are summarized in Table 2. In control conditions, CCh stimulated [³⁵S]GTP γ S binding in the three WT-hM4 cell lines at a similar potency but varying




Figure 7
GSNO increases the number of M2/M4 AChR interacting high-affinity [³⁵S]GTP γ S binding sites in rat forebrain membranes. Membranes were preincubated for 30 min in control conditions or in the presence of 0.5 mM GSNO, and incubated thereafter for 90 min with 0.15 nM [³⁵S]GTP γ S, 10^{-5} M GDP and indicated concentrations of unlabeled GTP γ S in the presence and absence of CCh (10^{-4} M), as detailed in the *Methods* section. Statistical comparison of one- versus two-site competition curves (nonlinear regression) indicated that the one-site model best described GTP γ S displacement in agonist-stimulated conditions. Note that GSNO significantly increased the number of high-affinity [³⁵S]GTP γ S binding sites in CCh-treated membranes (CCh-control 1.49 ± 0.02 ; CCh-GSNO 1.75 ± 0.02 pmol/mg protein, $P < 0.001$, unpaired T-test). There were no statistical differences in the potency for GTP γ S in displacing radioligand in any condition [$\log(EC_{50})$: basal-control -8.10 ± 0.07 ; basal-GSNO -8.11 ± 0.12 ; CCh-control -8.06 ± 0.06 ; CCh-GSNO -8.10 ± 0.04]. Values represent specific binding (mean \pm SE) from three independent experiments performed in duplicate.

efficacy (E_{max} ranging from 134 to 586 %) (Figure 8, Table 2). GSNO treatment significantly increased the E_{max} in the two WT-hM4 cell lines (E5 and C2) that showed comparable maximal responses to the values obtained in rat forebrain membranes (Figure 8, Table 2). In contrast, the potentiating effect of GSNO was lost in the WT-hM4-A1 cell line, where CCh robustly activated G proteins (Figure 8, Table 2). In contrast to the situation in brain membranes and other hM4 cell lines of this study, WT-hM4-A1 cell line exhibited constitutive activity, i.e. significant G protein activation was evident in the absence of added agonist. In this cell line, the mAChR antagonist, atropine,

Table 2: Effects of GSNO treatment on agonist (CCh) dose-response parameters in [³⁵S]GTPγS binding assays of hM4 cell line membranes. Membranes were preincubated in control conditions or in the presence of 0.5 mM GSNO for 30 min. Values are mean ± SE from three to four independent experiments performed in duplicate. E_{max} is expressed in percentage over basal with nonspecific binding subtracted.

CHO cell line	Control		GSNO	
	log(EC ₅₀)	E _{max} (%)	log(EC ₅₀)	E _{max} (%)
hM4-WT-A1	-4.87 ± 0.14	586 ± 31	-4.94 ± 0.09	674 ± 23
hM4-WT-E5	-4.87 ± 0.05	213 ± 3	-4.98 ± 0.13	276 ± 10**
hM4-WT-C2	-5.21 ± 0.20	134 ± 3	-5.27 ± 0.20	154 ± 8*
hM4-C133S-H2	-5.13 ± 0.10	198 ± 4	-5.12 ± 0.11	235 ± 6**

* Statistically different from control (P < 0.05)

** Statistically different from control (P < 0.01)

significantly inhibited basal G protein activity by 13 ± 3 % (mean ± SE, n = 3, P < 0.05) (Figure 8, bottom panel middle). The effect was dose-dependent [log(IC₅₀) -8.48 ± 0.23 (mean ± SE, n = 3)], indicating increased constitutive activation of WT-hM4 receptor in this cell line. Collectively these experiments indicate that the potentiating effect of GSNO on hM4 receptor responses was preserved under heterologous expression but that the effect was diminished with constitutive receptor activity.

The final experiments were intended to clarify whether cysteine 133 (C133), located adjacent to the G protein-interacting DRY-motif in the intracellular end of transmembrane helix 3 of the G_i-coupled muscarinic receptors (M2/M4), could serve as the molecular target of RSNO action. To this end, C133 was mutated into serine to reveal if the C133S mutation would abolish the effect of GSNO on the efficacy of CCh. However, GSNO treatment significantly increased E_{max} also in the mutant C133S-hM4 cell line (Figure 8, bottom panel right, Table 2), indicating that cysteine C133 of the hM4 receptor is not the specific target of RSNOs. The mutation did not affect the potency of CCh to activate G proteins via the hM4 receptor (Table 2).

Discussion

[³⁵S]GTPγS autoradiography of brain cryostat sections revealed a highly receptor-specific modulation of GPCR signaling by RSNOs in several receptor-enriched anatomical structures. This modulation was fully reversible upon addition of excess thiols. We have provided evidence indicating that S-nitrosylation, rather than other types of NO reactions or the NO – guanylyl cyclase – cGMP signaling pathway, was responsible for the observed effects. The RSNOs effects were receptor-specific, as signaling of some receptors was markedly potentiated (M2/M4 AChRs and α₂-adrenoceptors), whereas that of

others was clearly inhibited (P2Y₁₂, LPA and cannabinoid CB₁ receptors), while signaling of other receptors was only marginally affected (adenosine A₁, MOR, and ORL1 receptors) by comparable treatments. We further demonstrated that RSNOs can amplify M2/M4 receptor responses by increasing the rate of GDP/GTP exchange as well as the number of high-affinity G protein α subunits capable of interacting with the agonist-activated receptors. The potentiating effect of RSNOs on hM4 receptor responses was preserved when this was studied in a heterologous expression system but was diminished in constitutively active hM4 receptors. We also demonstrated that the GPCR itself or its native signaling partners serve as potential targets of this modulation, as it was attenuated, or even lost, when receptor signaling was studied under heterologous expression. Our study suggests that GPCR signaling is subject to a highly receptor-specific modulation by NO-derived RSNOs.

The GPCRs and their proximal signaling partners as likely targets of RSNO action

Since [³⁵S]GTPγS binding assays monitor G protein activation, one of the earliest measurable steps in GPCR signal transduction, it is obvious that the molecular targets of RSNO action are the receptors, their cognate G proteins and/or additional signaling partners, whose thiol modification can directly regulate guanine nucleotide binding and hence G protein activation.

It is interesting that RSNO treatment of brain sections consistently resulted in thiol-sensitive increases in basal G_i protein activity throughout the gray matter regions. However, no such effect was present in brain membrane [³⁵S]GTPγS binding assays, nor was it detected in CHO cell membranes but in platelet membranes, RSNOs inhibited basal G protein activity by ~20%. As receptor input should be minimal in basal conditions, the differential




Figure 8
GSNO-evoked potentiation of muscarinic signaling is preserved under heterologous expression but the effect diminishes with increasing constitutive activity. The human M4 (hM4) receptor was stably transfected into CHO cells and wild type (WT) or mutant (C133S) cell lines with differential G protein activation capacity were compared with that in rat forebrain membranes. CCh-stimulated G protein activity was determined in control conditions and in membranes pretreated for 30 min with 0.5 mM GSNO, as detailed in the *Methods* section. Note that cell lines WT-C2, WT-E5 and C133S-H2 have maximal responses comparable to that in native brain tissue. Note also robust G protein activation in WT-A1 cell line, as well as its constitutive activity, as evidenced by the ability of the inverse agonist atropine to inhibit basal G protein activity in this cell line. Potency and efficacy values are summarized in Tables 1 (rat brain) and 2 (hM4 clones). Values are mean \pm SE from at least three independent experiments performed in duplicate.

behavior of RSNOs in cryostat sections and various membrane preparations likely reflects direct action on the G_i proteins and/or their proximal regulatory partners. It has been known for some time that G proteins can serve as direct targets of ROS, including NO [21-24,28,29]. Exogenous NO donors stimulate the monomeric G protein p21^{ras} via S-nitrosylation to a single cysteine residue [22,53]. Furthermore, $G\alpha_i$ and $G\alpha_o$ serve as direct protein targets of ROS, and they can be activated in the absence of input from the GPCRs [29,33]. Specifically, ROS were shown to modify two cysteine residues of $G\alpha_{i/o}$ and this modification accelerated GDP release from $G\alpha$ with a concomitant increase in the formation of the GTP-bound form of $G\alpha$ without receptor activation [29,33]. Further-

more, GSNO was reported to stimulate basal G protein activity in bovine aortic endothelial cells and human peripheral blood mononuclear cells [22,26]. The RSNO-elicited increase in basal G protein activity in brain sections is consistent with these findings. However, it is not clear why no such stimulation was detected in bulk membrane preparations. One explanation could be the differential accessibility of target thiol(s) in cryostat sections as compared to membrane preparations. It is reasonable to assume that thiol accessibility in the former situation is close to natural. It is also possible that some crucial regulatory component of the signaling machinery is lost in bulk membrane preparations. Since several high-speed centrifugation steps were employed to obtain the

relatively pure membrane preparation used in our study, this possibility should not be underestimated. This could also explain why RSNOs had no effect on basal G protein activity in CHO cell membranes, although several members of the G_i family, including $G\alpha_{i1/2}$, $G\alpha_{i3}$, and $G\alpha_o$, are endogenously present in these cells [54].

In platelet membranes, RSNOs inhibited both basal and P2Y₁₂ receptor-dependent G protein activity, but clearly potentiated α_{2A} -adrenoceptor responses. Platelet P2Y₁₂ receptors couple to $G\alpha_{i2}$ [51,52], whereas α_{2A} -adrenoceptors can communicate via $G\alpha_z$, at least in the mouse [55]. Collectively these data suggest that RSNOs inhibit both basal and receptor-stimulated $G\alpha_{i2}$ activity in the platelets. It is not yet known whether brain P2Y₁₂ receptors couple to this particular G protein subtype. Further, it is unclear whether LPA receptors in brain and CHO cells communicate via $G\alpha_{i2}$. It is interesting that RSNOs inhibited the signaling of all three receptors in native tissues. In addition, we found that brain cannabinoid CB₁ receptor signaling was inhibited by RSNOs. A previous study reported that pulmonary vasoconstriction by serotonin was also inhibited by GSNO [34].

Although the basic module of GPCR signaling is traditionally considered to be the receptor, its cognate G protein, and the effector, recent studies have identified a wide range of proteins that can directly interact with the receptor and/or G proteins. These can modulate signaling efficiency, cellular localization, or the regulation of the GPCRs or G proteins [6]. One such recently-identified protein is the brain-enriched, Ras-related monomeric G protein Dexas1 (human counterpart is termed activator of G protein signaling 1, AGS1). Dexas1/AGS1 is physiologically activated upon NMDA receptor-stimulated NO synthesis and S-nitrosylation on cysteine C11 [56,57]. Dexas1/AGS-1 also interacts with $G\alpha_i/G\alpha_o$, and can activate GPCR signaling systems independently of receptor input [6,58]. Interestingly, Dexas1/AGS-1 was shown to proximally antagonize the signaling of M2 AChRs and formyl peptide receptors, possibly by altering the pool of G proteins available for receptor coupling and/or disruption of a preformed signaling complex [59,60]. It is currently unknown whether RSNOs and/or S-nitrosylation could alter the ability of Dexas1/AGS-1 to modify G protein function and/or input from the GPCRs. In light of the present findings, this should be an attractive hypothesis for future studies.

Most $G\alpha$ proteins are palmitoylated at a cysteine near the amino terminus and this modification is required for G protein targeting to lipid rafts [61] and/or normal signaling [62]. Addition and removal of the palmitoyl group appear to be dynamic receptor-mediated processes that may contribute to recycling of $G\alpha$ between the membrane

and cytosolic compartments [63]. Since our experiments used only nonliving tissue, it is unlikely that the RSNO actions would achieve such extensive lipid modifications, although such alterations reportedly occur after exposure of living cells to NO [64].

Functional implications

Specialized plasma membrane microdomains act as unique platforms with specific enrichment of GPCRs, their signaling partners, and the enzymatic machinery for NO biosynthesis [35,37-40]. Such close proximity of the GPCR signaling complex and NO source is particularly relevant for many of the receptors whose signaling was shown here to be reversibly modulated by RSNOs.

In the heart, endothelial NOS (eNOS) is localized in caveolin-enriched myocyte membrane fractions and it has been shown that lipid draft-disrupting agents severely compromise NO-dependent inhibition of adenylyl cyclase types 5 and 6 [35]. M2-mediated parasympathetic cardiac signaling also critically involves eNOS activation and NO production [65]. On the other hand, caveolar sequestration of M2 receptors and NO signaling was shown to be finely tuned in the myocytes [66], suggesting a dynamic interplay between the M2 receptor and NO. In hM4 expressing CHO cells, SNP induced agonist-independent internalization of the receptor via atropine- and thiol-sensitive mechanisms [67]. Furthermore, ROS including NO, potentiate cardiac M2 receptor signaling via poorly defined mechanisms [32,68]. Consistent with these findings, our study revealed robust amplification of M2/M4 receptor signaling by RSNOs both in the brain and in CHO cells expressing the hM4 receptor. In CHO cells, however, the RSNO effect clearly diminished with increasing constitutive receptor activity, suggesting that RSNO action and constitutive receptor activity likely share common mechanisms, including accelerated GDP/GTP exchange in cognate $G\alpha$ subunits. As far as we are aware, this is the first study to show robust, and highly region-specific amplification of M2/M4 receptor signaling in discrete anatomical loci of the central nervous system. The functional consequences of these findings remain to be established.

The P2Y₁₂ receptor plays a central role in platelet activation and aggregation [69]. Previous studies have indicated that endothelial and platelet-derived NO, as well as exogenous RSNOs, are potent inhibitors of platelet aggregation [70-73]. Both cGMP-dependent and -independent mechanisms and several potential molecular targets have been implicated in these effects [72,74]. A previous report provided evidence for cGMP-mediated signaling in the inhibition of platelet G_i signaling [74]. The present study adds further dimensions to this scheme by demonstrating that RSNOs can inhibit platelet (and brain) P2Y₁₂ receptor

function via cGMP-independent mechanisms, likely involving S-nitrosylation. However, since the effect was lost in CHO cells stably expressing the hP2Y₁₂ receptor, the native signaling partners, rather than the P2Y₁₂ receptor, serve as obvious targets of this action.

One of the novel findings in this study was that RSNOs strongly inhibited G_i-mediated LPA receptor signaling in the brain and in CHO cells. The relevance of this finding with respect to brain LPA₁ receptor signaling remains to be established. In vivo, peripheral LPA receptor signaling is closely associated with NO. In bovine aortic endothelial cells, LPA stimulates endothelial NOS via G_i-coupled LPA receptors [75]. LPA is released from activated platelets and this stimulates other platelets to activate aggregation processes [76,77]. Inhibition of LPA signaling via endogenous RSNOs could be one important mechanism by which endothelium-derived NO can suppress LPA-mediated athero- and thrombogenic signaling.

Conclusion

In conclusion, this study revealed that G protein activation, an early step of GPCR signal transduction, is subject to a reversible and highly receptor-specific modulation by exogenous RSNOs at physiologically relevant concentrations. Since NOS synthases (and thus NO production) have been shown to reside in close proximity with the GPCR signaling machinery, especially for many of the receptors whose signaling is subject to modulation by exogenous RSNOs, these findings suggest that GPCR signaling in vivo is likely to be finely tuned by NO-derived RSN0 species. Future studies should aim at pinpointing the precise molecular targets of these actions, and at understanding the specific modifications (S-nitrosylation and/or S-thiolation) involved, as well as revealing the physiological and/or pathophysiological relevance in vivo.

Methods

Materials

All drugs and chemicals were from Sigma (St. Louis, MO) or Merck (Darmstadt, Germany), unless otherwise stated. Cell culture media, sera, and antibiotics were from Euroclone (Pero, Italy). Protein concentrations were determined with Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Adenosine deaminase (ADA) was purchased from Roche (Mannheim, Germany) and guanosine-5'-O-(3-[³⁵S]-thio)-triphosphate ([³⁵S]GTPγS; initial specific activity 1250 Ci/mmol) from NEN (Boston, MA). CP55940, DAMGO, nociceptin, and SNAP were purchased from Tocris Cookson Ltd. (Bristol, UK).

DNA constructs

Human M4 muscarinic receptor (hM4, gift from Dr. Johnny Näsman, University of Kuopio) was subcloned

from pBluescript into pcDNA3 mammalian expression vector and a triple hemagglutinin (HA) epitope tag was subcloned after the initiating Met codon of the hM4 gene. This construct was used to create a C133S mutant hM4 receptor with QuickChange Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA). Human P2Y₁₂ purinergic receptor (hP2Y₁₂) was amplified from QuickClone human brain cDNA (Stratagene) using RT-PCR with gene-specific primers. The PCR product was ligated into pcDNA3 and a N-terminal hemagglutinin (HA) epitope tag was inserted in a PCR reaction with 5' primer containing the HA tag DNA sequence. All receptor constructs were confirmed by restriction analyses and DNA sequencing prior to transfections.

Cell culture and transfection

Recombinant plasmids were introduced into Chinese hamster ovary (CHO) cells with Lipofectamine 2000 transfection reagent (Gibco, Paisley, UK). Transfected cells were placed under G-418 selection (600 μg/ml) and several cell lines originating from single G-418 resistant cells were isolated. The G-418 resistant cell lines were cultured as monolayers with 100 μg/ml G-418 in Ham's F-12 nutrient mixture, containing 10% fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO₂ / 95% air. Stable cell lines were analyzed for HA tag (and thus receptor) expression using receptor ELISA with mouse anti-HA primary antibody [78]. The cell lines that showed high receptor expression levels in receptor ELISA were maintained for subsequent experiments. From these, several hM4 and hP2Y₁₂ cell lines were established that responded to carbachol (CCh) or 2-methylthio-ADP (2MeSADP), respectively. Nontransfected CHO cells did not respond to CCh (data not shown). CHO cells endogenously express G_q-coupled P2Y receptors (P2Y₁ and P2Y₂). However, CHO cells that had not been transfected with the hP2Y₁₂ receptor construct did not respond to 2MeSADP, indicating that activation of G_q was not detected using [³⁵S]GTPγS binding assays (data not shown).

Preparation of cryostat sections, membranes, and cell lysates

Naïve, four-week-old male Wistar rats were used for the preparation of brain cryostat sections essentially as described earlier [41,79]. All animal protocols were approved by the local ethics committee. Platelet membranes were prepared from expired human platelets (Red Cross, Helsinki, Finland) as previously described [42], except that protease inhibitor cocktail was omitted. CHO cells were harvested by scraping in PBS containing 5 mM EDTA. Membrane fractions (P2) from rat brains and hM4 cell lines were isolated with differential centrifugation using previously published protocols [80,81]. For membrane preparation from hP2Y₁₂-expressing cell lines, the

centrifugation method used for platelet membrane preparation [42] was used, with the modification of omitting the protease inhibitor cocktail. For the preparation of whole-cell lysates, the cells were harvested by trypsinization in normal growth medium. Cell density was counted in a hemocytometer and the cells were pelleted by centrifugation for 10 min at $250 \times g$ at room temperature. The cell pellets were washed with PBS and centrifuged twice as above, after which the dry pellets were snap-frozen on dry ice. The frozen pellets were thawed for 1 min in a water bath at room temperature, after which snap-freezing was repeated. The final membrane and lysate preparations (1–5 mg protein/ml) were stored as single-use aliquots in -75°C .

Preparation of S-nitrosothiols

S-nitroso-N-acetyl-D,L-penicillamine (SNAP) was purchased from Tocris Cookson Ltd. (Bristol, UK). All other RSNOs were synthesized from the respective thiols using acidified NaNO_2 . For example, S-nitrosoglutathione (GSNO) was prepared by mixing 100 μl sodium nitrite (100 mM) with 100 μl HCl (150 mM) and adding 100 μl reduced glutathione (100 mM). Reactions were allowed to proceed for 10 min at room temperature, protected from light. Reaction mixtures were neutralized with 150 μl NaOH (100 mM) and used immediately in the experiments. Millipore-quality water was used throughout and the assay buffer routinely contained 1 mM EDTA. The concentrations of RSNOs were determined by UV spectroscopy using previously published [70] values for the molar absorption coefficients (ϵ) and absorption maxima (λ_{max}).

[^{35}S]GTP γS autoradiography

The assay was conducted under optimized conditions, where basal noise due to tonic adenosine A_1 receptor activity has been eliminated [79]. Experiments were conducted in light-protected chambers and in the absence of dithiothreitol (DTT), unless indicated otherwise. Briefly, the assay consisted of preincubation for 20 min at 20°C in buffer A (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 100 mM NaCl, 5 mM MgCl_2), followed by GDP loading and RSNO treatment for 1 h at 20°C in buffer A, containing additionally 2 mM GDP and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 10^{-6} M) or adenosine deaminase (ADA, 1 U/ml) to eliminate tonic adenosine A_1 receptor activity. When peptide agonists were used, protease inhibitor cocktail (Sigma P-2714) was included in step 2 at the concentrations recommended by the manufacturer. For [^{35}S]GTP γS binding, sections were incubated for 90 min at 20°C in buffer A, containing additionally 80 pM [^{35}S]GTP γS , 2 mM GDP, DPCPX (10^{-6} M) or ADA (1 U/ml), and the receptor agonists and/or reduced thiols (DTT, GSH or cysteine), as detailed in the results section. Nonspecific binding (Nsb) was determined in the pres-

ence of 10 μM GTP γS . The sections were washed twice at 0°C for 5 min in washing buffer (50 mM Tris-HCl, 5 mM MgCl_2 , pH 7.4), rinsed in ice-cold deionized water for 30 s, air dried and apposed to Biomax™ MR film (Kodak) for 6–11 days. Autoradiography images were digitized and processed for figures, as previously described [41].

[^{35}S]GTP γS membrane binding assays

The incubations were carried with slight modifications to previously published protocols [80,81]. Membranes or lysates were preincubated for 30 min at room temperature in 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 100 mM NaCl, 5 mM MgCl_2 , 10 μM GDP and 0.5 U/ml ADA, under constant shaking and protected from light. RSNOs (usually GSNO or CysNO) were included in the preincubation at final concentrations of 0.5 mM. The assay was performed in duplicate in a final assay volume of 400 μl . The reaction was initiated by adding 40 μl of membrane or lysate preparation (5 μg protein or 50,000 cells / tube) to incubation tubes containing drug dilutions and binding cocktail. The final concentrations of the components in binding reaction were 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 100 mM NaCl, 5 mM MgCl_2 , 0.5% BSA, 10 μM GDP, 0.5 U/ml ADA and 150 pM [^{35}S]GTP γS . Nsb was defined using 10 μM GTP γS . Reaction tubes were incubated for 90 min at 25°C under constant shaking. The reaction was quickly terminated by the addition of 4 ml ice-cold wash buffer (50 mM Tris-HCl (pH 7.4), 5 mM MgCl_2) followed by rapid filtration through Whatman GF/B glass fiber filters (Whatman, Maidstone, UK) and two additional 4 ml washes with the buffer. In the time-response study (Figure 6), initial reaction volume was 2 ml and aliquots (400 μl) from duplicate samples were draw at different time points (15, 30, 60 and 90 min), and the reaction was terminated as described above. Radioactivity in filters was counted with Wallac Rackbeta liquid scintillation counter (Wallac, Turku, Finland). It should be noted that RSNO treatment caused a small, yet consistent increase in Nsb ($25 \pm 4\%$, mean \pm SEM, $n = 13$). However, as Nsb represented $<0.3\%$ of total radioactivity, this effect was considered negligible and did not contribute to the results and conclusions thereof.

Data analysis

[^{35}S]GTP γS -membrane binding data were analyzed with GraphPad Prism software (GraphPad, San Diego, CA) using non-linear fitting for sigmoid dose-response curves. Statistical analyses were made with one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. When comparison was made between only two groups, unpaired T-test was used.

List of abbreviations

2MeSADP, 2-methylthio-ADP; [^{35}S]GTP γS , guanosine-5'-O-(3-[^{35}S]-thio)-triphosphate; 5-HT, 5-hydroxytrypt-

tamine; ADA, adenosine deaminase; AGS, activator of G protein signaling; CCh, carbacholine; CHO, Chinese hamster ovary; CP-55940, (-)-3-[2-hydroxy-4-(1,1-dimethylheptyl)-phenyl]-4-[3-hydroxypropyl]cyclohexan-1-ol; CysNO, S-nitrosocysteine; CysNO-Gly, S-nitroso-cysteinyl-glycine; DAMGO, [D-Ala², N-Me-Phe⁴, Gly⁵-ol]-enkephalin; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; DTT, dithiotreitol; Glu-CysNO, L-γ-glutamyl-S-nitrosocysteine; GSH, glutathione; GPCR(s), G protein-coupled receptor(s); GSNO, S-nitrosoglutathione; HA, hemagglutinin; hM4, human muscarinic receptor subtype 4; hP2Y₁₂, human P2Y₁₂ purinergic receptor; LPA, lysophosphatidic acid; NA, noradrenaline; NO, nitric oxide; NOBF₄, nitrosodium tetrafluoroborate; NOS, NO synthase; RGS, regulator of G protein signaling; RT, reverse transcriptase; SNAP, S-nitroso-N-acetyl-D,L-penicillamine; RSNO, S-nitrosothiol; SNP, sodium nitroprusside

Authors' contributions

TK carried out the cell culture, molecular biology and mutagenesis studies, participated in the membrane and lysate [³⁵S]GTPγS binding assays, participated in the design of the study and drafted the manuscript. JRS and MDR carried out most of the membrane [³⁵S]GTPγS binding assays and performed the statistical analyses for these. KSM carried out G protein activation assays with human platelets. JTL conceived of the study, its design and coordination and conducted [³⁵S]GTPγS autoradiography experiments. All authors read and approved the final manuscript.

Additional material

Additional File 1

Supplementary material (Supplementary Figures 1, 2, 3, 4, 5, 6, 7 and Supplementary Tables 1, 2) is provided as a single file. This pdf-file (size 0.75 MB) is readable using Adobe Acrobat.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2121-6-21-S1.pdf>]

Acknowledgements

MDR is a medical student from Madrid, Spain and participated in this study as an IFMSA (International Federation of Medical Students' Association) exchange student. We wish to thank Dr. Johny Näsman (University of Kuopio) for the hM4 receptor cDNA, and Prof. Mika Scheinin (University of Turku) for the CHO cell lines expressing α₂-adrenoceptor subtypes. Reija Heikkinen (M.Sc.) is acknowledged for her contribution in the generation and functional testing of hM4 cell lines. Dr. Ewen MacDonald is acknowledged for the revision of the language of this paper. We are thankful to Mrs. Taina Vihavainen, Mrs. Tiina Räsänen and Mrs. Taija Vaarala for skillful technical assistance and to Mrs. Merja Saastamoinen for secretarial help.

References

1. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB: **The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogue groups, and fingerprints.** *Mol Pharmacol* 2003, **63**:1256-1272.
2. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA: **The G protein-coupled receptor repertoire of human and mouse.** *Proc Natl Acad Sci U S A* 2003, **100**:4903-4908.
3. Wise A, Gearing K, Rees S: **Target validation of G-protein coupled receptors.** *Drug Discov Today* 2002, **7**:235-246.
4. Pierce KL, Premont RT, Lefkowitz RJ: **Seven-transmembrane receptors.** *Nat Rev Mol Cell Biol* 2002, **3**:639-650.
5. Neubig RR, Siderovski DP: **Regulators of G-protein signalling as new central nervous system drug targets.** *Nat Rev Drug Discov* 2002, **1**:187-197.
6. Blumer JB, Lanier SM: **Accessory proteins for G protein-signaling systems: activators of G protein signaling and other non-receptor proteins influencing the activation state of G proteins.** *Receptors Channels* 2003, **9**:195-204.
7. Davis KL, Martin E, Turko IV, Murad F: **Novel effects of nitric oxide.** *Annu Rev Pharmacol Toxicol* 2001, **41**:203-236.
8. Liu Z, Rudd MA, Freedman JE, Loscalzo J: **S-Transnitrosation reactions are involved in the metabolic fate and biological actions of nitric oxide.** *J Pharmacol Exp Ther* 1998, **284**:526-534.
9. Arnette DR, Stamler JS: **NO⁺, NO, and NO⁻ donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation.** *Arch Biochem Biophys* 1995, **318**:279-285.
10. Ji Y, Akerboom TP, Sies H, Thomas JA: **S-nitrosylation and S-glutathiolation of protein sulfhydryls by S-nitroso glutathione.** *Arch Biochem Biophys* 1999, **362**:67-78.
11. Konorev EA, Kalyanaraman B, Hogg N: **Modification of creatine kinase by S-nitrosothiols: S-nitrosation vs. S-thiolation.** *Free Radic Biol Med* 2000, **28**:1671-1678.
12. Xian M, Chen X, Liu Z, Wang K, Wang PG: **Inhibition of papain by S-nitrosothiols. Formation of mixed disulfides.** *J Biol Chem* 2000, **275**:20467-20473.
13. Hess DT, Matsumoto A, Nudelman R, Stamler JS: **S-nitrosylation: spectrum and specificity.** *Nat Cell Biol* 2001, **3**:E46-E49.
14. Stamler JS, Lamas S, Fang FC: **Nitrosylation. The prototypic redox-based signaling mechanism.** *Cell* 2001, **106**:675-683.
15. Ahern GP, Klyachko VA, Jackson MB: **cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO.** *Trends Neurosci* 2002, **25**:510-517.
16. Hogg N: **The biochemistry and physiology of S-nitrosothiols.** *Annu Rev Pharmacol Toxicol* 2002, **42**:585-600.
17. Tao L, English AM: **Protein S-glutathiolation triggered by decomposed S-nitrosoglutathione.** *Biochemistry* 2004, **43**:4028-4038.
18. Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A, Bankston LA: **Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation.** *Trends Neurosci* 2002, **25**:474-480.
19. Foster MW, McMahon TJ, Stamler JS: **S-nitrosylation in health and disease.** *Trends Mol Med* 2003, **9**:160-168.
20. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS: **Protein S-nitrosylation: purview and parameters.** *Nat Rev Mol Cell Bio* 2005, **6**:150-166.
21. Ehret-Hilberer S, Nullans G, Aunis D, Virmaux N: **Mono ADP-ribosylation of transducin catalyzed by rod outer segment extract.** *FEBS Lett* 1992, **309**:394-398.
22. Lander HM, Sehajpal PK, Novogrodsky A: **Nitric oxide signaling: a possible role for G proteins.** *J Immunol* 1993, **151**:7182-7187.
23. Pozdnyakov N, Lloyd A, Reddy VN, Sitaramayya A: **Nitric oxide-regulated endogenous ADP-ribosylation of rod outer segment proteins.** *Biochem Biophys Res Commun* 1993, **192**:610-615.
24. Hess DT, Lin LH, Freeman JA, Norden JJ: **Modification of cysteine residues within G(o) and other neuronal proteins by exposure to nitric oxide.** *Neuropharmacology* 1994, **33**:1283-1292.
25. Pozdnyakov N, Margulis A, Sitaramayya A: **Endogenous ADP-ribosylation of a G(alpha i) protein in bovine ciliary body is stimulated by nitric oxide.** *Biochem Biophys Res Commun* 1997, **235**:482-486.

26. Miyamoto A, Laufs U, Pardo C, Liao JK: **Modulation of bradykinin receptor ligand binding affinity and its coupled G-proteins by nitric oxide.** *J Biol Chem* 1997, **272**:19601-19608.
27. McVey M, Hill J, Howlett A, Klein C: **Adenylyl cyclase, a coincidence detector for nitric oxide.** *J Biol Chem* 1999, **274**:18887-18892.
28. Naganuma T, Maekawa M, Murayama T, Nomura Y: **Effects of S-nitroso-cysteine on proteins that regulate exocytosis in PC12 cells: inhibitory effects on translocation of synaptophysin and ADP-ribosylation of GTP-binding proteins.** *Jpn J Pharmacol* 2000, **84**:391-398.
29. Nishida M, Maruyama Y, Tanaka R, Kontani K, Nagao T, Kurose H: **G alpha(i) and G alpha(o) are target proteins of reactive oxygen species.** *Nature* 2000, **408**:492-495.
30. Hill J, Howlett A, Klein C: **Nitric oxide selectively inhibits adenylyl cyclase isoforms 5 and 6.** *Cell Signal* 2000, **12**:233-237.
31. Hudson TY, Corbett JA, Howlett AC, Klein C: **Nitric oxide regulates adenylyl cyclase activity in rat striatal membranes.** *J Neurochem* 2001, **77**:1279-1284.
32. Peters SL, Sand C, Batinik HD, Pfaffendorf M, van Zwieten PA: **Reactive oxygen species potentiate the negative inotropic effect of cardiac M2-muscarinic receptor stimulation.** *Naunyn-Schmiedeberg Arch Pharmacol* 2001, **364**:166-171.
33. Nishida M, Schey KL, Takagahara S, Kontani K, Katada T, Urano Y, Nagano T, Nagao T, Kurose H: **Activation mechanism of Gi and Go by reactive oxygen species.** *J Biol Chem* 2002, **277**:9036-9042.
34. Nozik-Grayck E, McMahon TJ, Huang YC, Dieterle CS, Stamler JS, Piantadosi CA: **Pulmonary vasoconstriction by serotonin is inhibited by S-nitroso-glutathione.** *Am J Physiol Lung Cell Mol Physiol* 2002, **282**:L1057-L1065.
35. Ostrom RS, Bunday RA, Insel PA: **Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes.** *J Biol Chem* 2004, **279**:19846-19853.
36. Laitinen JT: **[35S]GTPγS Autoradiography: A powerful functional approach with expanding potential for neuropharmacological studies on receptors coupled to Gi family of G proteins.** *Current Neuropharmacology* 2004, **2**:191-206.
37. Ostrom RS, Liu X, Head BP, Gregorian C, Seasholtz TM, Insel PA: **Localization of adenylyl cyclase isoforms and G protein-coupled receptors in vascular smooth muscle cells: expression in caveolin-rich and noncaveolin domains.** *Mol Pharmacol* 2002, **62**:983-992.
38. Bourova L, Kostrova A, Hejnova L, Moravcova Z, Moon HE, Novotny J, Milligan G, Svoboda P: **delta-Opioid receptors exhibit high efficiency when activating trimeric G proteins in membrane domains.** *J Neurochem* 2003, **85**:34-49.
39. Foster LJ, De Hoog CL, Mann M: **Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors.** *Proc Natl Acad Sci U S A* 2003, **100**:5813-5818.
40. Insel P: **Location, location, location.** *Trends Endocrinol Metab* 2003, **14**:100-102.
41. Laitinen JT, Uri A, Raidaru G, Miettinen R: **[35S]GTPγS autoradiography reveals a wide distribution of Gi/o-linked ADP receptors in the nervous system: close similarities with the platelet P2YADP receptor.** *J Neurochem* 2001, **77**:505-518.
42. Vasiljev KS, Uri A, Laitinen JT: **2-Alkylthio-substituted platelet P2Y12 receptor antagonists reveal pharmacological identity between the rat brain Gi-linked ADP receptors and P2Y12.** *Neuropharmacology* 2003, **45**:145-154.
43. Waeber C, Chiu ML: **In vitro autoradiographic visualization of guanosine-5'-O-(3-[35S]thio)triphosphate binding stimulated by sphingosine 1-phosphate and lysophosphatidic acid.** *J Neurochem* 1999, **73**:1212-1221.
44. Capece ML, Baghdoyan HA, Lydic R: **Carbachol stimulates [35S]guanylyl 5'-(gamma-thio)-triphosphate binding in rapid eye movement sleep-related brainstem nuclei of rat.** *J Neurosci* 1998, **18**:3779-3785.
45. Demarco GJ, Baghdoyan HA, Lydic R: **Differential cholinergic activation of G proteins in rat and mouse brainstem: relevance for sleep and nociception.** *J Comp Neurol* 2003, **457**:175-184.
46. Gaston B, Reilly J, Drazen JM, Fackler J, Ramdev P, Arnelle D, Mullins ME, Sugarbaker DJ, Chee C, Singel DJ: **Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways.** *Proc Natl Acad Sci U S A* 1993, **90**:10957-10961.
47. Kluge I, Gutteck-Amsler U, Zollinger M, Do KQ: **S-nitrosoglutathione in rat cerebellum: identification and quantification by liquid chromatography-mass spectrometry.** *J Neurochem* 1997, **69**:2599-2607.
48. Jalink K, Hordijk PL, Moolenaar WH: **Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator.** *Biochim Biophys Acta* 1994, **1198**:185-196.
49. Huber CM, Saffrich R, Ansorge W, Just WW: **Receptor-mediated regulation of peroxisomal motility in CHO and endothelial cells.** *EMBO J* 1999, **18**:5476-5485.
50. McAllister G, Stanton JA, Salim K, Handford EJ, Beer MS: **Edg2 receptor functionality: galpha1 coexpression and fusion protein studies.** *Mol Pharmacol* 2000, **58**:407-412.
51. Ohlmann P, Laugwitz KL, Nurnberg B, Spicher K, Schultz G, Cazenave JP, Gachet C: **The human platelet ADP receptor activates Gi2 proteins.** *Biochem J* 1995, **312**:775-779.
52. Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM: **Impaired activation of murine platelets lacking G alpha(i2).** *J Clin Invest* 2001, **108**:477-483.
53. Lander HM, Hajjar DP, Hempstead BL, Mirza UA, Chait BT, Campbell S, Quilliam LA: **A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction.** *J Biol Chem* 1997, **272**:4323-4326.
54. Selkirk JV, Price GW, Nahorski SR, Challiss RA: **Cell type-specific differences in the coupling of recombinant mGlu1alpha receptors to endogenous G protein sub-populations.** *Neuropharmacology* 2001, **40**:645-656.
55. Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O'Brien PJ, Manning D, Poncz M, Lucki I, Blendy JA, Brass LF: **Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs.** *Proc Natl Acad Sci USA* 2000, **97**:9984-9989.
56. Fang M, Jaffrey SR, Sawa A, Ye K, Luo X, Snyder SH: **Dexas1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON.** *Neuron* 2000, **28**:183-193.
57. Jaffrey SR, Fang M, Snyder SH: **Nitrosopeptide mapping: a novel methodology reveals s-nitrosylation of dexas1 on a single cysteine residue.** *Chem Biol* 2002, **9**:1329-1335.
58. Graham TE, Qiao Z, Dorin RL: **Dexas1 inhibits adenylyl cyclase.** *Biochem Biophys Res Commun* 2004, **316**:307-312.
59. Graham TE, Prossnitz ER, Dorin RL: **Dexas1/AGS-1 inhibits signal transduction from the Gi-coupled formyl peptide receptor to Erk-1/2 MAP kinases.** *J Biol Chem* 2002, **277**:10876-10882.
60. Takesono A, Nowak MW, Cismowski M, Duzic E, Lanier SM: **Activator of G-protein signaling I blocks GIRK channel activation by a G-protein-coupled receptor: apparent disruption of receptor signaling complexes.** *J Biol Chem* 2002, **277**:13827-13830.
61. Dunphy JT, Greentree WK, Linder ME: **Enrichment of G-protein palmitoyltransferase activity in low density membranes: in vitro reconstitution of Galpha1 to these domains requires palmitoyltransferase activity.** *J Biol Chem* 2001, **276**:43300-43304.
62. Wedegaertner PB, Chu DH, Wilson PT, Levis MJ, Bourne HR: **Palmitoylation is required for signaling functions and membrane attachment of Gq alpha and Gs alpha.** *J Biol Chem* 1993, **268**:25001-25008.
63. Sprang SR: **G proteins, effectors and GAPs: structure and mechanism.** *Curr Opin Struct Biol* 1997, **7**:849-856.
64. Adam L, Bouvier M, Jones TL: **Nitric oxide modulates beta(2)-adrenergic receptor palmitoylation and signaling.** *J Biol Chem* 1999, **274**:26337-26343.
65. Han X, Kubota I, Feron O, Opel DJ, Arstall MA, Zhao YY, Huang P, Fishman MC, Michel T, Kelly RA: **Muscarinic cholinergic regulation of cardiac myocyte ICa-L is absent in mice with targeted disruption of endothelial nitric oxide synthase.** *Proc Natl Acad Sci U S A* 1998, **95**:6510-6515.
66. Dessy C, Kelly RA, Balligand JL, Feron O: **Dynamin mediates caveolar sequestration of muscarinic cholinergic receptors and alteration in NO signaling.** *EMBO J* 2000, **19**:4272-4280.
67. Maggio R, Barbier P, Toso A, Barletta D, Corsini GU: **Sodium nitroprusside induces internalization of muscarinic receptors stably expressed in Chinese hamster ovary cell lines.** *J Neurochem* 1995, **65**:943-946.
68. Abi-Gerges N, Szabo G, Otero AS, Fischmeister R, Mery PF: **NO donors potentiate the beta-adrenergic stimulation of I(Ca,L)**

- and the muscarinic activation of I(K,ACh) in rat cardiac myocytes. *J Physiol* 2002, **540**:411-424.
69. Dorsam RT, Kunapuli SP: **Central role of the P2Y12 receptor in platelet activation.** *J Clin Invest* 2004, **113**:340-345.
 70. Tullett JM, Rees DD, Shuker DE, Gescher A: **Lack of correlation between the observed stability and pharmacological properties of S-nitroso derivatives of glutathione and cysteine-related peptides.** *Biochem Pharmacol* 2001, **62**:1239-1247.
 71. Radomski MW, Rees DD, Dutra A, Moncada S: **S-nitroso-glutathione inhibits platelet activation in vitro and in vivo.** *Br J Pharmacol* 1992, **107**:745-749.
 72. Gordge M P, Hothersall JS, Noronha-Dutra AA: **Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.** *Br J Pharmacol* 1998, **124**:141-148.
 73. Freedman JE, Sauter R, Battinelli EM, Ault K, Knowles C, Huang PL, Loscalzo J: **Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene.** *Circ Res* 1999, **84**:1416-1421.
 74. Aktas B, Honig-Liedl P, Walter U, Geiger J: **Inhibition of platelet P2Y12 and alpha2A receptor signaling by cGMP-dependent protein kinase.** *Biochem Pharmacol* 2002, **64**:433-439.
 75. Kou R, Igarashi J, Michel T: **Lysophosphatidic acid and receptor-mediated activation of endothelial nitric-oxide synthase.** *Biochemistry* 2002, **41**:4982-4988.
 76. Karliner JS: **Lysophospholipids and the cardiovascular system.** *Biochim Biophys Acta* 2002, **1582**:216-221.
 77. Siess W: **Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate.** *Biochim Biophys Acta* 2002, **1582**:204-215.
 78. Kokkola T, Foord SM, Watson MA, Vakkuri O, Laitinen JT: **Important amino acids for the function of the human MT1 melatonin receptor.** *Biochem Pharmacol* 2003, **65**:1463-1471.
 79. Laitinen JT: **Selective detection of adenosine A1 receptor-dependent G-protein activity in basal and stimulated conditions of rat brain [35S]guanosine 5'-(gamma-thio)triphosphate autoradiography.** *Neuroscience* 1999, **90**:1265-1279.
 80. Kurkinen KM, Koistinaho J, Laitinen JT: **Gamma-35S]GTP autoradiography allows region-specific detection of muscarinic receptor-dependent G-protein activation in the chick optic tectum.** *Brain Res* 1997, **769**:21-28.
 81. Savinainen JR, Järvinen T, Laine K, Laitinen JT: **Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes.** *Br J Pharmacol* 2001, **134**:664-672.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

